Board of Directors
Barbara Domayne-Hayman, DPhil
Dr Barbara Domayne-Hayman is Non-Executive Chairman of the Board and has a broad range of commercial, fund-raising and general management experience, with many years of business development. She is currently Chief Business Officer at Autifony Therapeutics and until Jan 2015 she was ‘Entrepreneur-in-residence’ at the Stevenage Bioscience Catalyst. Barbara was CEO of Stabilitech, a platform technology company, for over four years where she raised funding, including non-dilutive, and established twelve commercial collaborations. Previously she was Commercial Director at Arrow Therapeutics, an antiviral drug discovery and development company, until the company was acquired by AstraZeneca in 2007. Prior to Arrow, Barbara was Senior Business Development Manager at Celltech. She previously held senior international commercial strategy and marketing positions at Zeneca where she worked for over ten years. She holds a Sloan Fellowship from London Business School and has a BA and D.Phil in chemistry, from the University of Oxford.
Steve has more than 30 years of successful business leadership experience in pharmaceuticals, biotechnology and life sciences markets with global giants including Millipore Corporation and GE Healthcare. He has deep domain experience in designing and implementing successful business strategies, building and leading teams and developing the potential of technologies and companies. More than half of his career has been overseas. Today, Steve is a Senior Partner with Xtendium, an advisory group focusing on strategy, company development and M&A activity across life sciences and digital healthcare markets. Steve has a BSc in Microbiology from Leeds University and studied at INSEAD Business School in Fontainebleau, France.
Inga is in the Healthcare Ventures team at Imperial Innovations, specialising in investments across medical devices, therapeutics, diagnostics, and healthcare, including digital health. She is currently a Director at Puridify and Ieso Digital Health and a board observer at Veryan Medical. Previously she worked in business development and technology transfer at the London Bioscience Innovation Centre/Royal Veterinary College in London, commercializing research, sourcing and building industry collaborations. She completed a DPhil and MSc in Neuroscience from the University of Oxford, sponsored by the Wellcome Trust. Her first degree was Natural Sciences from the University of Cambridge.
Matthew joined SR One in 2011 to take the lead in investing SR One’s UK biotech fund. Prior to joining SR One he worked as a consultant for Longbow Capital Partners in London. Before that he was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm, where he worked in New York for eight years up until 2010.
Matthew holds a BSc / MA in molecular biology from St Peter’s College, University of Oxford; a Certificate in Corporate Finance from The London Business School and various FSA & SEC qualifications.
Oliver Hardick, EngD
Oliver is the Chief Executive Officer and founder of Puridify. He created and developed the patented technology behind FibroSelect during his Engineering Doctorate at UCL. His expertise lie with Downstream Processing technologies for biomolecule manufacture from ultra-scale-down to pilot processing. He has experience as director of multiple companies and has strong links to UK BioIndustry.